{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:16:18Z","timestamp":1790946978845,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.atherosclerosis.2016.10.037","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T18:48:24Z","timestamp":1476989304000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"special_numbering":"C","title":["Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review"],"prefix":"10.1016","volume":"255","author":[{"given":"Katrine Laura","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib1","series-title":"World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1504327","article-title":"Incidence of dementia over three decades in the Framingham heart study","volume":"374","author":"Satizabal","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ijcard.2012.10.046","article-title":"Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations","volume":"168","author":"Finegold","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer's disease: an analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib8","series-title":"World Alzheimer Report 2014. Dementia and Risk Reduction. An Analysis of Protective and Modifiable Factors","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib9","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2835","article-title":"Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism","author":"Mahley","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM196701052760107","article-title":"Fat transport in lipoproteins\u2013an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib11","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1073\/pnas.70.7.2015","article-title":"Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins","volume":"70","author":"Havel","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/269604a0","article-title":"Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man","volume":"269","author":"Utermann","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib13","first-page":"11","article-title":"Human apolipoprotein E isoprotein subclasses are genetically determined","volume":"33","author":"Zannis","year":"1981","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0022-2275(20)38094-9","article-title":"Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes","volume":"23","author":"Zannis","year":"1982","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib15","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","article-title":"Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms","volume":"256","author":"Weisgraber","year":"1981","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib16","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1073\/pnas.79.15.4696","article-title":"Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects","volume":"79","author":"Rall","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib17","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1016\/S0021-9258(18)34702-1","article-title":"Human apolipoprotein E. The complete amino acid sequence","volume":"257","author":"Rall","year":"1982","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","article-title":"Association of apolipoprotein E genotypes with lipid levels and coronary risk","volume":"298","author":"Bennet","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib19","first-page":"268","article-title":"Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation","volume":"37","author":"Sing","year":"1985","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib20","first-page":"104","article-title":"Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism","volume":"42","author":"Boerwinkle","year":"1988","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01790099","article-title":"Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels","volume":"80","author":"Smit","year":"1988","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1098-2272(200004)18:4<331::AID-GEPI6>3.0.CO;2-V","article-title":"ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels","volume":"18","author":"Neale","year":"2000","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.24326","article-title":"Plasma levels of apolipoprotein E and risk of dementia in the general population","volume":"77","author":"Rasmussen","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.ATV.8.1.1","article-title":"Apolipoprotein E polymorphism and atherosclerosis","volume":"8","author":"Davignon","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib26","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1172\/JCI112704","article-title":"Familial apolipoprotein E deficiency","volume":"78","author":"Schaefer","year":"1986","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","article-title":"Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function","volume":"71","author":"Mak","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","article-title":"Apolipoprotein E: structure-function relationships","volume":"45","author":"Weisgraber","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/bi00507a059","article-title":"Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification","volume":"20","author":"Zannis","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib30","first-page":"3","article-title":"Context-dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease: a review","volume":"233","author":"Frikke-Schmidt","year":"2000","journal-title":"Scand. J. Clin. Lab. Investig. Suppl."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-5793(97)01543-3","article-title":"Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene","volume":"421","author":"Artiga","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00439-004-1165-z","article-title":"Gender- and age-specific contributions of additional DNA sequence variation in the 5' regulatory region of the APOE gene to prediction of measures of lipid metabolism","volume":"115","author":"Frikke-Schmidt","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib33","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R800069-JLR200","article-title":"Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS","volume":"50","author":"Mahley","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib34","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1073\/pnas.1207022109","article-title":"Garai K. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease","volume":"109","author":"Frieden","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib35","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/bi1020106","article-title":"Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles","volume":"50","author":"Garai","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib36","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/S0021-9258(18)34954-8","article-title":"Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site","volume":"257","author":"Weisgraber","year":"1982","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nsb0896-718","article-title":"Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia","volume":"3","author":"Dong","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1172\/JCI112645","article-title":"Abnormal in\u00a0vivo metabolism of apolipoprotein E4 in humans","volume":"78","author":"Gregg","year":"1986","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0022-2275(20)42621-5","article-title":"Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112","volume":"31","author":"Weisgraber","year":"1990","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib40","doi-asserted-by":"crossref","first-page":"9273","DOI":"10.1021\/bi2010027","article-title":"Hydrogen\/deuterium exchange and electron-transfer dissociation mass spectrometry determine the interface and dynamics of apolipoprotein E oligomerization","volume":"50","author":"Huang","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib41","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1074\/jbc.M110.151084","article-title":"Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease","volume":"286","author":"Chen","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmb.2008.12.040","article-title":"Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy","volume":"386","author":"Hatters","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib43","first-page":"173","article-title":"Apolipoprotein E mutants, hyperlipidemia and arteriosclerosis","volume":"183","author":"Utermann","year":"1985","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030176","article-title":"ApoE plasma levels and risk of cardiovascular mortality in old age","volume":"3","author":"Mooijaart","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0021-9150(99)00501-8","article-title":"Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project","volume":"152","author":"Schiele","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/clinchem\/44.5.957","article-title":"Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study","volume":"44","author":"Vincent-Viry","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","article-title":"Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides","volume":"11","author":"Simon","year":"2012","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","article-title":"Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease","volume":"69","author":"Soares","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(98)00889-1","article-title":"Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease","volume":"259","author":"Scacchi","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(98)00339-5","article-title":"Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study","volume":"248","author":"Slooter","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib51","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1126\/science.6795720","article-title":"Type III hyperlipoproteinemia associated with apolipoprotein E deficiency","volume":"214","author":"Ghiselli","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/0003-4819-98-5-623","article-title":"NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment","volume":"98","author":"Brewer","year":"1983","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib53","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/ATVBAHA.112.300353","article-title":"Identification of a functional apolipoprotein E promoter polymorphism regulating plasma apolipoprotein E concentration","volume":"33","author":"Mannila","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib54","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0022-2275(20)37876-7","article-title":"Sex-related differences in the concentrations of apolipoprotein E in human blood plasma and plasma lipoproteins","volume":"24","author":"Phillips","year":"1983","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib55","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1172\/JCI109988","article-title":"Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency","volume":"66","author":"Havel","year":"1980","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0009-8981(87)90024-6","article-title":"A\u00a0simple immunotechnique for the determination of serum concentration of apolipoprotein E","volume":"163","author":"Rifai","year":"1987","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0006-291X(86)90302-5","article-title":"A\u00a0rapid apolipoprotein E radioimmunoassay using solid-phase staphylococcus protein. Use of pooled plasma as a secondary standard","volume":"138","author":"Au","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.ejhg.5200864","article-title":"The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe","volume":"10","author":"Haddy","year":"2002","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib59","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib60","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0021-9258(17)33600-1","article-title":"Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts","volume":"251","author":"Bersot","year":"1976","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib61","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2705","article-title":"Introduction: structure and metabolism of plasma lipoproteins","author":"Havel","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib62","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/MOL.0b013e328338cabc","article-title":"Recent insights into factors affecting remnant lipoprotein uptake","volume":"21","author":"Williams","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.ATV.17.1.149","article-title":"Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB\/E receptor","volume":"17","author":"Olsson","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/00365518909089080","article-title":"Concentrations of apolipoproteins B, C-I, C-II, C-III, E and lipids in serum and serum lipoproteins of normal subjects during alimentary lipaemia","volume":"49","author":"Annuzzi","year":"1989","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib65","doi-asserted-by":"crossref","first-page":"26388","DOI":"10.1074\/jbc.273.41.26388","article-title":"Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia","volume":"273","author":"Huang","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/JMN:23:3:189","article-title":"Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease","volume":"23","author":"Huang","year":"2004","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1073\/pnas.82.1.203","article-title":"Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets","volume":"82","author":"Elshourbagy","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","article-title":"Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins","volume":"917","author":"Pitas","year":"1987","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib70","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","article-title":"Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus","volume":"26","author":"Xu","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ajmg.b.30993","article-title":"APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure","volume":"153B","author":"Bekris","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1172\/JCI115288","article-title":"Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation","volume":"88","author":"Linton","year":"1991","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-008-0012-2","article-title":"Why lipids are important for Alzheimer disease?","volume":"326","author":"Hirsch-Reinshagen","year":"2009","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib75","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","article-title":"Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism","volume":"36","author":"Mahley","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib76","doi-asserted-by":"crossref","first-page":"e001156","DOI":"10.1161\/JAHA.114.001156","article-title":"Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus","volume":"3","author":"Stukas","year":"2014","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.2000.tb06365.x","article-title":"Lipoproteins in the central nervous system","volume":"903","author":"Ladu","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib78","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","article-title":"Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system","volume":"27","author":"Bell","year":"2007","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib79","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jalz.2015.04.006","article-title":"Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease","volume":"11","author":"Nordestgaard","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1197-263","article-title":"Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition","volume":"17","author":"Bales","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib81","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","article-title":"Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease","volume":"96","author":"Bales","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib82","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","article-title":"Apolipoprotein E in Alzheimer's disease: an update","volume":"37","author":"Yu","year":"2014","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib83","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neuron.2012.11.020","article-title":"Apolipoprotein e sets the stage: response to injury triggers neuropathology","volume":"76","author":"Mahley","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib84","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.1434398100","article-title":"Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice","volume":"100","author":"Harris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib85","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z","article-title":"Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype","volume":"48","author":"Gibson","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib86","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A","volume":"485","author":"Bell","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib88","doi-asserted-by":"crossref","first-page":"17536","DOI":"10.1074\/jbc.M111.225532","article-title":"Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in\u00a0vitro blood-brain barrier model","volume":"286","author":"Nishitsuji","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib89","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib90","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib91","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib93","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","article-title":"ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in\u00a0vivo","volume":"41","author":"DeMattos","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood-brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib97","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0022-2275(20)41380-X","article-title":"Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene","volume":"33","author":"Lohse","year":"1992","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib98","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib99","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer's disease","volume":"17","author":"Hort","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","article-title":"Apolipoprotein E in Alzheimer's disease and other neurological disorders","volume":"10","author":"Verghese","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib101","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMoa0809437","article-title":"Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect","volume":"361","author":"Caselli","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib102","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jalz.2013.05.1763","article-title":"APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease","volume":"10","author":"Chang","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib103","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","article-title":"Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging","volume":"76","author":"Gupta","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib104","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/CCLM.2000.102","article-title":"Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group","volume":"38","author":"Siest","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib105","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib106","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jalz.2013.03.010","article-title":"High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia","volume":"10","author":"Vijayaraghavan","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib107","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1046\/j.1471-4159.1997.69051995.x","article-title":"Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta","volume":"69","author":"Martel","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0014-4886(03)00185-7","article-title":"Differential metabolism of ApoE isoforms in plasma and CSF","volume":"183","author":"Wahrle","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-4886(03)00088-8","article-title":"APOE epsilon 3\/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis","volume":"183","author":"Fukumoto","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ana.24355","article-title":"Apolipoprotein E levels and Alzheimer risk","volume":"77","author":"Hyman","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib111","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","article-title":"Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease","volume":"79","author":"Hu","year":"2012","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.10.037_bib112","article-title":"In\u00a0vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis","volume":"8","author":"Ulrich","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib113","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","article-title":"apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain","volume":"118","author":"Deane","year":"2008","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neulet.2016.02.018","article-title":"Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: the Rotterdam Study","volume":"617","author":"Wolters","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2015.12.038","article-title":"Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population","volume":"246","author":"Rasmussen","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-141-2-200407200-00013","article-title":"Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease","volume":"141","author":"Song","year":"2004","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib118","doi-asserted-by":"crossref","first-page":"e95463","DOI":"10.1371\/journal.pone.0095463","article-title":"Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib119","doi-asserted-by":"crossref","first-page":"e104608","DOI":"10.1371\/journal.pone.0104608","article-title":"Meta-analysis of apolipoprotein e gene polymorphism and susceptibility of myocardial infarction","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.atherosclerosis.2014.07.038","article-title":"A\u00a0systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease","volume":"237","author":"Holmes","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib121","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.metabol.2011.11.010","article-title":"Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein","volume":"61","author":"Corsetti","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib122","doi-asserted-by":"crossref","first-page":"e39110","DOI":"10.1371\/journal.pone.0039110","article-title":"Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein","volume":"7","author":"Corsetti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib123","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/CIRCULATIONAHA.104.526848","article-title":"Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)","volume":"112","author":"Packard","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib124","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/S0021-9258(17)34612-4","article-title":"Apoprotein (E\u2013A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction","volume":"253","author":"Weisgraber","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib125","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1016\/S0021-9258(17)34613-6","article-title":"Apoprotein (E\u2013A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E\u2013A-II) complex","volume":"253","author":"Innerarity","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib126","doi-asserted-by":"crossref","first-page":"e000130","DOI":"10.1161\/JAHA.113.000130","article-title":"Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease","volume":"2","author":"Mendivil","year":"2013","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2016.10.037_bib127","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501631440X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501631440X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T21:33:12Z","timestamp":1657488792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501631440X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":127,"alternative-id":["S002191501631440X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.037","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}